PE20090282A1 - Azetidinas como agentes antagonistas de ep2 - Google Patents

Azetidinas como agentes antagonistas de ep2

Info

Publication number
PE20090282A1
PE20090282A1 PE2008000813A PE2008000813A PE20090282A1 PE 20090282 A1 PE20090282 A1 PE 20090282A1 PE 2008000813 A PE2008000813 A PE 2008000813A PE 2008000813 A PE2008000813 A PE 2008000813A PE 20090282 A1 PE20090282 A1 PE 20090282A1
Authority
PE
Peru
Prior art keywords
carboxyl
methyl
azetidin
oxy
optionally substituted
Prior art date
Application number
PE2008000813A
Other languages
English (en)
Inventor
Kevin Neil Dack
Sarah Elizabeth Skerratt
Siew Kuen Yeap
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of PE20090282A1 publication Critical patent/PE20090282A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DE AZETIDINA DE FORMULA (I), DONDE R1 ES UN GRUPO TETRAHIDROPIRANILO O UN FENILO OPCIONALMENTE SUSTITUIDO CON ALQUILO C1-C4, F, PERFLUOROALQUILO C1-C6, ENTRE OTROS; X ES UN ENLACE DIRECTO O NH; Z ES -C(=O)-O-R2, -C(=O)-NH-SO2R3 O CN; R2 Y R3 SON H O ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO CON FLUOR; Ar ES UN GRUPO AROMATICO CONSTITUIDO POR 1 A 3 ANILLOS AROMATICOS SELECCIONADOS DE FENILO Y UN ANILLO HETEROAROMATICO DE 5 O 6 MIEMBROS QUE CONTIENE DE 1 A 3 HETEROATOMOS TALES COMO N, O Y S. SON COMPUESTOS PREFERIDOS: ACIDO 1-(4-FLUOROBENZOIL)-3-{[(66-METOXI-2-NAFTIL)OXI]METIL}AZETIDIN-3-CARBOXILICO, ACIDO 3-{[(2'-CLOROBIFENIL-4-IL)OXI]METIL}-1-(4-FLUOROBENZOIL)AZETIDIN-3-CARBOXILICO, ACIDO 1-BENZOIL-3-{[(5-FENILPIRAZIN-2-IL)OXI]METIL}AZETIDIN-3-CARBOXILICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR 2 DE PROSTAGLANDINAS E2 (PGE2) O EP2 Y SON UTILES EN EL TRATAMIENTO DE ENDOMETRIOSIS, MIOMAS UTERINOS, ADENOMIOSIS, ENTRE OTROS
PE2008000813A 2007-05-10 2008-05-08 Azetidinas como agentes antagonistas de ep2 PE20090282A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91708107P 2007-05-10 2007-05-10
US1303007P 2007-12-12 2007-12-12

Publications (1)

Publication Number Publication Date
PE20090282A1 true PE20090282A1 (es) 2009-03-27

Family

ID=39739736

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000813A PE20090282A1 (es) 2007-05-10 2008-05-08 Azetidinas como agentes antagonistas de ep2

Country Status (27)

Country Link
US (1) US20080280877A1 (es)
EP (1) EP2155666A1 (es)
JP (1) JP2010526801A (es)
KR (1) KR20100009582A (es)
CN (1) CN101679235A (es)
AP (1) AP2009005047A0 (es)
AR (1) AR066524A1 (es)
AU (1) AU2008249744A1 (es)
BR (1) BRPI0811444A2 (es)
CA (1) CA2686517A1 (es)
CL (1) CL2008001305A1 (es)
CO (1) CO6260066A2 (es)
CR (1) CR11101A (es)
DO (1) DOP2009000256A (es)
EA (1) EA200901381A1 (es)
EC (1) ECSP099727A (es)
GT (1) GT200900293A (es)
IL (1) IL201874A0 (es)
MA (1) MA31366B1 (es)
MX (1) MX2009011998A (es)
PA (1) PA8779601A1 (es)
PE (1) PE20090282A1 (es)
SV (1) SV2009003407A (es)
TN (1) TN2009000470A1 (es)
TW (1) TW200904409A (es)
UY (1) UY31070A1 (es)
WO (1) WO2008139287A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2222665A1 (en) * 2007-11-15 2010-09-01 Pfizer Limited Azetidines as ep2 antagonists
AP2011005728A0 (en) * 2008-11-10 2011-06-30 Pfizer Ltd Pyrrolidines.
KR20120028867A (ko) * 2009-04-02 2012-03-23 알러간, 인코포레이티드 프로스타글란딘 ｅ 수용체 길항제
DE102009049662A1 (de) 2009-10-13 2011-04-14 Bayer Schering Pharma Aktiengesellschaft 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten
WO2013010679A1 (en) * 2011-07-15 2013-01-24 Novartis Ag Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
JP2017538769A (ja) 2014-12-22 2017-12-28 ファイザー・インク プロスタグランジンｅｐ３受容体の拮抗薬
CN110041269A (zh) * 2019-05-16 2019-07-23 海门瑞一医药科技有限公司 一种2-氯-5-羟基嘧啶的制备方法
EP4359399A1 (en) * 2021-06-24 2024-05-01 Reservoir Neuroscience, Inc. Ep2 antagonist compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8300860D0 (en) * 1983-01-13 1983-02-16 Shell Int Research Azetidine compounds
GB8415614D0 (en) * 1984-06-19 1984-07-25 Shell Int Research Azetidine derivatives
GB8509746D0 (en) * 1985-04-16 1985-05-22 Shell Int Research Preparing azetidine derivatives
TW200300757A (en) 2001-11-16 2003-06-16 Schering Corp Azetidinyl diamines useful as ligands of the nociceptin receptor orl-1
CA3052368A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors
US8383660B2 (en) * 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives

Also Published As

Publication number Publication date
DOP2009000256A (es) 2009-11-30
TN2009000470A1 (fr) 2011-03-31
ECSP099727A (es) 2009-12-28
CN101679235A (zh) 2010-03-24
CO6260066A2 (es) 2011-03-22
BRPI0811444A2 (pt) 2014-10-29
MX2009011998A (es) 2009-11-19
IL201874A0 (en) 2010-06-16
CA2686517A1 (en) 2008-11-20
SV2009003407A (es) 2010-01-12
UY31070A1 (es) 2009-01-05
PA8779601A1 (es) 2009-01-23
CL2008001305A1 (es) 2008-07-18
EP2155666A1 (en) 2010-02-24
JP2010526801A (ja) 2010-08-05
MA31366B1 (fr) 2010-05-03
US20080280877A1 (en) 2008-11-13
AU2008249744A1 (en) 2008-11-20
CR11101A (es) 2009-12-04
EA200901381A1 (ru) 2010-06-30
WO2008139287A1 (en) 2008-11-20
AR066524A1 (es) 2009-08-26
AP2009005047A0 (en) 2009-12-31
TW200904409A (en) 2009-02-01
KR20100009582A (ko) 2010-01-27
GT200900293A (es) 2010-05-17

Similar Documents

Publication Publication Date Title
PE20090282A1 (es) Azetidinas como agentes antagonistas de ep2
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20091843A1 (es) Inhibidores de catepsina c
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
PE20131117A1 (es) Derivados de bencimidazol como inhibidores de prostaglandinas
AR074676A1 (es) Derivados de isooxazol como antagonistas de receptores de acido lisofosfatidico, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la actividad fisiologica de lpa.
PE20081838A1 (es) Derivados de ester o amida de imidazolilo como moduladores del receptor glucocorticoide
PE20120355A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20091828A1 (es) Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino como inhibidores de edg-2
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
PE20141726A1 (es) Heterociclilaminas como inhibidores de pi 3k
PE20130576A1 (es) Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10
PE20081704A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
PE20060627A1 (es) Derivados de pirazol condensado como agonistas de los receptores cannabinoides cb1 y/o cb2
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
HRP20110498T1 (hr) Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
PE20060306A1 (es) Compuestos de heteroaril-amida sustituida
AR053092A1 (es) Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis
AR061058A1 (es) Derivados de piridopirimidininona. procesos de obtencion y composiciones farmaceuticas
PE20091444A1 (es) Derivados de isoxazolo-pirazina
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
PE20051054A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
AR065093A1 (es) Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos
PE20141041A1 (es) Compuestos, metodos y formulaciones parasiticidas

Legal Events

Date Code Title Description
FD Application declared void or lapsed